Biggest Seed, Series A-E and Venture Investments within Oncology January 2024.
View the report at the bottom of this page.
January 2024 Snapshot:
177 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 3,843,000,000.00 total true investment received in USA and EU within the Oncology sector in January 2024 across 38 different biotechs.
Some Notable True Oncology Investments
✅Accent Therapeutics - $750,00,000(Series C): 3x Preclinical, and IND-Enabling for oncology trials
✅Ratio Therapeutics - $ 50,000,000 (Series B): first patient dosed in Phase I study evaluating a novel FAP-Targeted radiopharmaceutical for PET imaging
✅ GlycoEra - (Undisclosed Amount -Series A): target selection for oncology phase trial, lead ID, 2x pre-lead ID, and target selection for autoimmune diseases
✅ Plus 30+ companies in the report.
Seen some big exits by RayzeBio and POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company end of December. Some big Series Cs and an IPO from Immatics (one of the best companies in the world, but I might be bias) in this report. Also another 3bn exit from MorphoSys (Feb).
Download the report here
